Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry

[1]  M. Thill,et al.  [The 20-year results of 5‑year hormone therapy in breast cancer : Early Breast Cancer Trialists' Collaborative Group (EBCTCG)]. , 2018, Der Internist.

[2]  M. Kiechle,et al.  Survival of de novo stage IV breast cancer patients over three decades , 2016, Journal of Cancer Research and Clinical Oncology.

[3]  J. Forbes,et al.  Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials , 2015, The Lancet.

[4]  Andrew Menzies,et al.  Subclonal diversification of primary breast cancer revealed by multiregion sequencing , 2015, Nature Medicine.

[5]  M. de Boer,et al.  Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? , 2015, British Journal of Cancer.

[6]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[7]  L. Moja,et al.  Trastuzumab-containing regimens for metastatic breast cancer. , 2014, The Cochrane database of systematic reviews.

[8]  C. Köhne,et al.  Metastatic breast cancer: are we treating the same patients as in the past? , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Marisa C. Jenkins,et al.  Combination versus sequential single agent chemotherapy for metastatic breast cancer. , 2013, The Cochrane database of systematic reviews.

[10]  Z. Werb,et al.  Roadblocks to translational advances on metastasis research , 2013, Nature Medicine.

[11]  U. Kleeberg,et al.  Adjuvant Therapy Reduces the Benefit of Palliative Treatment in Disseminated Breast Cancer - Own Findings and Review of the Literature , 2013, Oncology Research and Treatment.

[12]  D. Hershman,et al.  Comparative effectiveness research in oncology methodology: observational data. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  L. Moja,et al.  Trastuzumab containing regimens for early breast cancer. , 2012, The Cochrane database of systematic reviews.

[14]  Irmtraud M. Meyer,et al.  The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.

[15]  R. Peto,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. , 2012, Lancet.

[16]  R. Arceci.  Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing , 2012 .

[17]  R Peto,et al.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[18]  J. Coebergh,et al.  Unfavourable pattern of metastases in M0 breast cancer patients during 1978-2008: a population-based analysis of the Munich Cancer Registry , 2011, Breast Cancer Research and Treatment.

[19]  V. Tjan-Heijnen,et al.  Improved survival of patients with primary distant metastatic breast cancer in the period of 1995–2008. A nationwide population-based study in the Netherlands , 2011, Breast Cancer Research and Treatment.

[20]  G. Hortobagyi,et al.  Survival differences among women with de novo stage IV and relapsed breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[22]  R. Emeny,et al.  Distant metastases do not metastasize , 2010, Cancer and Metastasis Reviews.

[23]  J. Cuzick,et al.  Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Ryan D. Morin,et al.  Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.

[25]  S. French,et al.  Metastatic patterns of cancers: results from a large autopsy study. , 2009, Archives of pathology & laboratory medicine.

[26]  M. Namer,et al.  Prognostic factors in 1,038 women with metastatic breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  Kristine Broglio,et al.  Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Odd O Aalen,et al.  Breast cancer tumor growth estimated through mammography screening data , 2008, Breast Cancer Research.

[29]  Martin A. Nowak,et al.  Comparative lesion sequencing provides insights into tumor evolution , 2008, Proceedings of the National Academy of Sciences.

[30]  L. Gibson,et al.  Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. , 2007, The Cochrane database of systematic reviews.

[31]  J. Talmadge,et al.  Clonal selection of metastasis within the life history of a tumor. , 2007, Cancer research.

[32]  D. Ghersi,et al.  Taxanes for adjuvant treatment of early breast cancer. , 2007, The Cochrane database of systematic reviews.

[33]  L. Akslen,et al.  Role of Angiogenesis in Human Tumor Dormancy: Animal Models of the Angiogenic Switch , 2006, Cell cycle.

[34]  Dongsheng Tu,et al.  Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  D. Ghersi,et al.  Taxane containing regimens for metastatic breast cancer. , 2003, The Cochrane database of systematic reviews.

[36]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[37]  Mike Clarke,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992 .

[38]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[39]  C. Redmond,et al.  Significance of ipsilateral breast tumour recurrence after lumpectomy , 1991, The Lancet.

[40]  B. Fisher.  Laboratory and clinical research in breast cancer--a personal adventure: the David A. Karnofsky memorial lecture. , 1980, Cancer research.

[41]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.